Pre-surgery imatinib for high-risk stomach or gut GIST
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed, primary (not spread from elsewhere) GIST in your gastrointestinal tract
- Your tumor tests positive for specific markers: c-Kit (CD117) and/or DOG-1
- Your tumor’s gene report includes test results for c-kit exons 9, 11, 13, and 17 and PDGFRA exons 12 and 18
- Your GIST is “high risk” by size—stomach tumor bigger than 10 cm, or non-stomach tumor bigger than 5 cm
- You’re age 18–80, and your overall health is good (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two oral medications, imatinib and fampridine, before surgery can shrink GIST tumors that have a specific KIT gene mutation. The goal is to improve surgical outcomes and potentially reduce the risk of the tumor coming back.
This trial tests whether taking imatinib before surgery can shrink a rectal GIST (a rare tumor) and make “rectum-sparing” surgery more possible. It is for people whose tumor has a specific c-KIT gene mutation and who can’t safely get a complete local resection at the start.
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
Hear when a new Progression-Free Survival trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.